| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Coronary Artery Disease | 16 | 2020 | 147 | 1.570 |
Why?
|
| Plants | 2 | 2021 | 94 | 1.430 |
Why?
|
| Benzophenones | 3 | 2015 | 7 | 1.320 |
Why?
|
| Adjuvants, Immunologic | 6 | 2017 | 106 | 1.320 |
Why?
|
| Stents | 14 | 2017 | 59 | 1.110 |
Why?
|
| Intercellular Adhesion Molecule-1 | 4 | 2014 | 53 | 1.090 |
Why?
|
| Biological Products | 3 | 2014 | 67 | 1.030 |
Why?
|
| Coronary Restenosis | 13 | 2016 | 26 | 1.010 |
Why?
|
| Plants, Medicinal | 3 | 2023 | 54 | 1.010 |
Why?
|
| Drugs, Chinese Herbal | 2 | 2014 | 20 | 1.000 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2022 | 121 | 0.990 |
Why?
|
| Coronary Stenosis | 11 | 2016 | 36 | 0.940 |
Why?
|
| Photoaffinity Labels | 2 | 2016 | 3 | 0.940 |
Why?
|
| Withania | 1 | 2023 | 4 | 0.940 |
Why?
|
| Macrophages | 5 | 2019 | 431 | 0.900 |
Why?
|
| Cullin Proteins | 1 | 2022 | 11 | 0.870 |
Why?
|
| Lipopolysaccharides | 2 | 2023 | 200 | 0.860 |
Why?
|
| Dipeptides | 1 | 2021 | 29 | 0.830 |
Why?
|
| Caulobacteraceae | 1 | 2021 | 1 | 0.820 |
Why?
|
| Stearic Acids | 1 | 2021 | 5 | 0.820 |
Why?
|
| Alteromonas | 1 | 2021 | 4 | 0.820 |
Why?
|
| Peptides, Cyclic | 1 | 2021 | 30 | 0.810 |
Why?
|
| Herbal Medicine | 2 | 2014 | 8 | 0.810 |
Why?
|
| Cell Culture Techniques | 2 | 2021 | 136 | 0.810 |
Why?
|
| Humans | 107 | 2023 | 34853 | 0.740 |
Why?
|
| DNA Damage | 1 | 2022 | 341 | 0.720 |
Why?
|
| Lipids | 6 | 2014 | 222 | 0.670 |
Why?
|
| Japan | 28 | 2021 | 296 | 0.670 |
Why?
|
| Drug-Eluting Stents | 8 | 2020 | 31 | 0.660 |
Why?
|
| Proteome | 2 | 2012 | 132 | 0.650 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 2 | 2008 | 9 | 0.630 |
Why?
|
| Food Microbiology | 1 | 2017 | 34 | 0.620 |
Why?
|
| Ginkgolides | 1 | 2016 | 2 | 0.600 |
Why?
|
| Cholesterol, LDL | 8 | 2017 | 63 | 0.570 |
Why?
|
| Aged | 48 | 2020 | 6448 | 0.560 |
Why?
|
| Lactoylglutathione Lyase | 1 | 2015 | 4 | 0.550 |
Why?
|
| Dendritic Cells | 3 | 2017 | 112 | 0.530 |
Why?
|
| Myocardial Infarction | 5 | 2014 | 221 | 0.510 |
Why?
|
| Male | 70 | 2023 | 18870 | 0.510 |
Why?
|
| Probiotics | 1 | 2014 | 25 | 0.510 |
Why?
|
| Coronary Angiography | 14 | 2020 | 92 | 0.500 |
Why?
|
| Glucosylceramides | 1 | 2014 | 3 | 0.500 |
Why?
|
| Employment | 3 | 2020 | 73 | 0.500 |
Why?
|
| Coronary Vessels | 10 | 2017 | 93 | 0.500 |
Why?
|
| Bacteria | 1 | 2017 | 245 | 0.490 |
Why?
|
| Molecular Structure | 6 | 2021 | 467 | 0.490 |
Why?
|
| Temporal Bone | 3 | 2014 | 3 | 0.490 |
Why?
|
| Mandibular Condyle | 3 | 2014 | 6 | 0.490 |
Why?
|
| Light | 3 | 2013 | 180 | 0.490 |
Why?
|
| Registries | 8 | 2020 | 330 | 0.470 |
Why?
|
| Middle Aged | 48 | 2020 | 9642 | 0.460 |
Why?
|
| Hippocampus | 1 | 2016 | 546 | 0.460 |
Why?
|
| Cholesterol, HDL | 5 | 2017 | 87 | 0.450 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 5 | 2013 | 37 | 0.440 |
Why?
|
| Heart Failure | 2 | 2013 | 230 | 0.440 |
Why?
|
| Animals | 31 | 2023 | 14307 | 0.430 |
Why?
|
| Cell Line | 9 | 2023 | 1289 | 0.420 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2012 | 77 | 0.420 |
Why?
|
| Female | 67 | 2020 | 19873 | 0.420 |
Why?
|
| Avidin | 1 | 2011 | 5 | 0.410 |
Why?
|
| Proteomics | 2 | 2012 | 302 | 0.410 |
Why?
|
| Endothelial Cells | 4 | 2007 | 296 | 0.410 |
Why?
|
| Enzyme Inhibitors | 6 | 2008 | 396 | 0.400 |
Why?
|
| Heat-Shock Proteins | 1 | 2011 | 51 | 0.400 |
Why?
|
| Streptomyces | 1 | 2011 | 18 | 0.390 |
Why?
|
| Escherichia coli | 2 | 2021 | 436 | 0.390 |
Why?
|
| Temporomandibular Joint | 2 | 2011 | 3 | 0.380 |
Why?
|
| Diterpenes | 1 | 2011 | 83 | 0.380 |
Why?
|
| Plant Preparations | 1 | 2010 | 21 | 0.370 |
Why?
|
| Molecular Probes | 2 | 2012 | 23 | 0.370 |
Why?
|
| Mice | 19 | 2023 | 5668 | 0.370 |
Why?
|
| Nanoparticles | 1 | 2014 | 294 | 0.360 |
Why?
|
| Plant Extracts | 4 | 2023 | 250 | 0.350 |
Why?
|
| Cells, Cultured | 13 | 2014 | 1442 | 0.350 |
Why?
|
| Drug Design | 1 | 2010 | 154 | 0.340 |
Why?
|
| Thrombosis | 2 | 2012 | 61 | 0.330 |
Why?
|
| Lipoproteins, HDL | 4 | 2019 | 43 | 0.320 |
Why?
|
| Muscle, Smooth, Vascular | 3 | 2008 | 127 | 0.320 |
Why?
|
| Loranthaceae | 3 | 2011 | 3 | 0.320 |
Why?
|
| Stereoisomerism | 4 | 2021 | 162 | 0.310 |
Why?
|
| Monocytes | 3 | 2005 | 258 | 0.310 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2007 | 6 | 0.310 |
Why?
|
| Jurkat Cells | 4 | 2013 | 72 | 0.310 |
Why?
|
| Structure-Activity Relationship | 4 | 2021 | 376 | 0.310 |
Why?
|
| Atherosclerosis | 4 | 2019 | 131 | 0.310 |
Why?
|
| Sirolimus | 5 | 2012 | 58 | 0.300 |
Why?
|
| Interleukin-1beta | 1 | 2007 | 66 | 0.300 |
Why?
|
| Receptors, Chemokine | 2 | 2005 | 68 | 0.300 |
Why?
|
| Cyclooxygenase 2 | 1 | 2007 | 92 | 0.300 |
Why?
|
| Antigens, CD1d | 2 | 2017 | 5 | 0.290 |
Why?
|
| Follow-Up Studies | 13 | 2020 | 964 | 0.290 |
Why?
|
| Galactosylceramides | 2 | 2017 | 11 | 0.290 |
Why?
|
| Fluorescent Antibody Technique | 12 | 2017 | 185 | 0.290 |
Why?
|
| Nasopharyngeal Neoplasms | 12 | 1986 | 15 | 0.290 |
Why?
|
| Malaria Vaccines | 2 | 2017 | 20 | 0.290 |
Why?
|
| Apolipoproteins E | 1 | 2007 | 129 | 0.280 |
Why?
|
| Treatment Outcome | 14 | 2020 | 1349 | 0.280 |
Why?
|
| Staining and Labeling | 1 | 2006 | 100 | 0.280 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2006 | 109 | 0.280 |
Why?
|
| Molecular Probe Techniques | 1 | 2005 | 7 | 0.270 |
Why?
|
| Genome | 1 | 2006 | 117 | 0.270 |
Why?
|
| Hot Temperature | 1 | 2006 | 120 | 0.270 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2006 | 145 | 0.260 |
Why?
|
| Acute Coronary Syndrome | 3 | 2017 | 35 | 0.260 |
Why?
|
| Flow Cytometry | 3 | 2017 | 392 | 0.250 |
Why?
|
| Angina Pectoris | 6 | 2010 | 18 | 0.250 |
Why?
|
| Tomography, Spiral Computed | 3 | 2008 | 5 | 0.250 |
Why?
|
| Retrospective Studies | 12 | 2020 | 1961 | 0.240 |
Why?
|
| Floods | 2 | 2013 | 6 | 0.240 |
Why?
|
| Protein Binding | 4 | 2015 | 913 | 0.240 |
Why?
|
| Lymph Nodes | 4 | 2015 | 67 | 0.240 |
Why?
|
| Chemokines, CXC | 1 | 2003 | 35 | 0.240 |
Why?
|
| Bile Acids and Salts | 1 | 2023 | 31 | 0.230 |
Why?
|
| Protein Kinase C-delta | 1 | 2023 | 14 | 0.230 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2000 | 176 | 0.230 |
Why?
|
| Cardiovascular Diseases | 3 | 2019 | 628 | 0.230 |
Why?
|
| Phospholipase D | 1 | 2023 | 47 | 0.230 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2020 | 206 | 0.230 |
Why?
|
| Proteins | 1 | 2005 | 352 | 0.220 |
Why?
|
| Ubiquitins | 1 | 2022 | 45 | 0.220 |
Why?
|
| Genomic Instability | 1 | 2022 | 34 | 0.210 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 968 | 0.210 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 600 | 0.210 |
Why?
|
| Diketopiperazines | 1 | 2021 | 1 | 0.210 |
Why?
|
| Signal Transduction | 4 | 2020 | 1802 | 0.210 |
Why?
|
| Circular Dichroism | 1 | 2021 | 60 | 0.210 |
Why?
|
| Antihypertensive Agents | 4 | 2009 | 284 | 0.210 |
Why?
|
| Acetogenins | 2 | 2013 | 7 | 0.200 |
Why?
|
| Insurance, Long-Term Care | 2 | 2018 | 2 | 0.200 |
Why?
|
| Anticholesteremic Agents | 3 | 2012 | 23 | 0.200 |
Why?
|
| Child Abuse | 1 | 2021 | 60 | 0.200 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2023 | 147 | 0.200 |
Why?
|
| Furans | 2 | 2013 | 34 | 0.200 |
Why?
|
| Organogenesis | 1 | 2020 | 16 | 0.190 |
Why?
|
| Eyelid Neoplasms | 1 | 2000 | 1 | 0.190 |
Why?
|
| Cilia | 1 | 2020 | 23 | 0.190 |
Why?
|
| Cone-Beam Computed Tomography | 2 | 2011 | 13 | 0.190 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 195 | 0.190 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2000 | 14 | 0.190 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2000 | 13 | 0.190 |
Why?
|
| Heptanoic Acids | 2 | 2012 | 12 | 0.190 |
Why?
|
| Pistacia | 1 | 2020 | 3 | 0.190 |
Why?
|
| Adult | 28 | 2020 | 11034 | 0.190 |
Why?
|
| Chromatography, Liquid | 1 | 2021 | 140 | 0.190 |
Why?
|
| Radiation Monitoring | 1 | 2020 | 7 | 0.190 |
Why?
|
| Hedgehog Proteins | 1 | 2020 | 45 | 0.190 |
Why?
|
| Health Services Needs and Demand | 2 | 2018 | 143 | 0.180 |
Why?
|
| Time Factors | 9 | 2020 | 1681 | 0.180 |
Why?
|
| Antigens, CD | 3 | 2011 | 116 | 0.180 |
Why?
|
| Pyrroles | 2 | 2012 | 54 | 0.180 |
Why?
|
| Mass Spectrometry | 1 | 2021 | 255 | 0.180 |
Why?
|
| Sex Factors | 4 | 2017 | 859 | 0.180 |
Why?
|
| Toxicity Tests | 1 | 2019 | 42 | 0.180 |
Why?
|
| Risk Factors | 10 | 2021 | 3414 | 0.180 |
Why?
|
| Antineoplastic Agents | 3 | 2013 | 756 | 0.180 |
Why?
|
| Biofilms | 1 | 2021 | 166 | 0.170 |
Why?
|
| Conservation of Natural Resources | 1 | 2019 | 32 | 0.170 |
Why?
|
| Endothelium, Vascular | 5 | 2018 | 229 | 0.170 |
Why?
|
| Renal Dialysis | 2 | 2014 | 119 | 0.170 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 63 | 0.170 |
Why?
|
| Health Services for the Aged | 1 | 2018 | 17 | 0.170 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 70 | 0.170 |
Why?
|
| Home Care Services | 1 | 2018 | 29 | 0.160 |
Why?
|
| Malaria | 2 | 2017 | 68 | 0.160 |
Why?
|
| Residential Facilities | 1 | 2018 | 6 | 0.160 |
Why?
|
| Immunoconjugates | 1 | 2017 | 6 | 0.160 |
Why?
|
| Helicobacter pylori | 3 | 2003 | 105 | 0.160 |
Why?
|
| Natural Killer T-Cells | 3 | 2017 | 9 | 0.160 |
Why?
|
| Colonic Neoplasms | 1 | 2000 | 181 | 0.160 |
Why?
|
| Adenocarcinoma | 1 | 2000 | 239 | 0.160 |
Why?
|
| Brachial Artery | 1 | 2018 | 31 | 0.160 |
Why?
|
| Fluorescent Dyes | 2 | 2017 | 173 | 0.160 |
Why?
|
| Imidazoles | 4 | 2013 | 124 | 0.160 |
Why?
|
| Alkaline Phosphatase | 1 | 2017 | 48 | 0.160 |
Why?
|
| Blotting, Western | 2 | 2012 | 834 | 0.160 |
Why?
|
| Ambulatory Care | 1 | 2018 | 76 | 0.160 |
Why?
|
| Spleen | 6 | 2011 | 192 | 0.160 |
Why?
|
| Colorectal Neoplasms | 1 | 2023 | 413 | 0.160 |
Why?
|
| Vasodilation | 1 | 2018 | 65 | 0.160 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2011 | 281 | 0.160 |
Why?
|
| Career Mobility | 1 | 2017 | 24 | 0.160 |
Why?
|
| Food Handling | 1 | 2017 | 33 | 0.150 |
Why?
|
| Foodborne Diseases | 1 | 2017 | 22 | 0.150 |
Why?
|
| Lysophospholipids | 3 | 2008 | 19 | 0.150 |
Why?
|
| Sphingosine | 3 | 2008 | 21 | 0.150 |
Why?
|
| Adenoviridae | 1 | 2017 | 59 | 0.150 |
Why?
|
| Albuminuria | 1 | 2018 | 76 | 0.150 |
Why?
|
| Calcinosis | 2 | 2008 | 56 | 0.150 |
Why?
|
| Food Contamination | 1 | 2017 | 55 | 0.150 |
Why?
|
| Child | 13 | 2021 | 2875 | 0.150 |
Why?
|
| Blood Glucose | 4 | 2014 | 333 | 0.150 |
Why?
|
| Neoplasms | 3 | 2020 | 1033 | 0.150 |
Why?
|
| B-Lymphocytes | 6 | 1980 | 181 | 0.150 |
Why?
|
| Adiponectin | 4 | 2011 | 52 | 0.150 |
Why?
|
| Herpesvirus 4, Human | 5 | 1985 | 33 | 0.150 |
Why?
|
| Peptides | 1 | 2019 | 308 | 0.140 |
Why?
|
| Lymphocyte Activation | 5 | 2017 | 222 | 0.140 |
Why?
|
| Food | 1 | 2017 | 95 | 0.140 |
Why?
|
| Antibodies | 6 | 1979 | 135 | 0.140 |
Why?
|
| Postoperative Complications | 1 | 2017 | 206 | 0.140 |
Why?
|
| Blood Pressure | 5 | 2013 | 613 | 0.140 |
Why?
|
| Ultrasonography, Interventional | 3 | 2012 | 16 | 0.140 |
Why?
|
| Microtubules | 1 | 2016 | 113 | 0.140 |
Why?
|
| Tetrazoles | 2 | 2013 | 49 | 0.130 |
Why?
|
| Aged, 80 and over | 9 | 2018 | 2333 | 0.130 |
Why?
|
| Serum Amyloid P-Component | 2 | 2012 | 20 | 0.130 |
Why?
|
| Caregivers | 1 | 2017 | 167 | 0.130 |
Why?
|
| Angelica sinensis | 1 | 2014 | 1 | 0.130 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 2011 | 10 | 0.130 |
Why?
|
| Rahnella | 1 | 2014 | 3 | 0.130 |
Why?
|
| Interpersonal Relations | 1 | 2016 | 198 | 0.130 |
Why?
|
| Collateral Circulation | 2 | 2006 | 10 | 0.130 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 2 | 2006 | 129 | 0.130 |
Why?
|
| Metagenomics | 1 | 2014 | 32 | 0.130 |
Why?
|
| Coronary Circulation | 2 | 2006 | 27 | 0.130 |
Why?
|
| Lectins, C-Type | 2 | 2011 | 35 | 0.130 |
Why?
|
| Biguanides | 1 | 2014 | 7 | 0.130 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2014 | 4 | 0.130 |
Why?
|
| Amino Acid Sequence | 2 | 2008 | 1124 | 0.130 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2006 | 64 | 0.130 |
Why?
|
| Molecular Sequence Data | 2 | 2008 | 1490 | 0.120 |
Why?
|
| Temporomandibular Joint Disorders | 1 | 2014 | 4 | 0.120 |
Why?
|
| Carcinoma | 7 | 1986 | 94 | 0.120 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2014 | 165 | 0.120 |
Why?
|
| Social Support | 1 | 2016 | 356 | 0.120 |
Why?
|
| C-Reactive Protein | 2 | 2012 | 147 | 0.120 |
Why?
|
| Heart Sounds | 1 | 2013 | 1 | 0.120 |
Why?
|
| Lymphocytes | 5 | 2003 | 116 | 0.120 |
Why?
|
| Multivariate Analysis | 5 | 2017 | 570 | 0.120 |
Why?
|
| Kidney Transplantation | 3 | 1979 | 85 | 0.120 |
Why?
|
| Carbohydrates | 1 | 2013 | 28 | 0.120 |
Why?
|
| Sanitary Engineering | 1 | 2013 | 2 | 0.120 |
Why?
|
| Ranitidine | 2 | 2003 | 4 | 0.120 |
Why?
|
| Physical Therapy Modalities | 1 | 2013 | 30 | 0.120 |
Why?
|
| Urbanization | 1 | 2013 | 11 | 0.120 |
Why?
|
| Patient Care Team | 1 | 2013 | 44 | 0.120 |
Why?
|
| Particle Size | 1 | 2014 | 200 | 0.120 |
Why?
|
| Biphenyl Compounds | 1 | 2013 | 52 | 0.110 |
Why?
|
| Diabetes Mellitus | 2 | 2018 | 465 | 0.110 |
Why?
|
| Range of Motion, Articular | 2 | 2011 | 30 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2014 | 152 | 0.110 |
Why?
|
| Helicobacter Infections | 2 | 2003 | 74 | 0.110 |
Why?
|
| Insulin | 1 | 2014 | 224 | 0.110 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2014 | 107 | 0.110 |
Why?
|
| Environment | 1 | 2013 | 130 | 0.110 |
Why?
|
| Azetidines | 1 | 2012 | 7 | 0.110 |
Why?
|
| Sensitivity and Specificity | 3 | 2010 | 555 | 0.110 |
Why?
|
| Disaster Planning | 1 | 2013 | 51 | 0.110 |
Why?
|
| Peptide Nucleic Acids | 1 | 2012 | 1 | 0.110 |
Why?
|
| Adolescent | 14 | 2014 | 5035 | 0.110 |
Why?
|
| Cell Extracts | 1 | 2012 | 16 | 0.110 |
Why?
|
| Venous Thrombosis | 1 | 2012 | 27 | 0.110 |
Why?
|
| Pentacyclic Triterpenes | 1 | 2011 | 2 | 0.110 |
Why?
|
| Adenine | 1 | 2012 | 43 | 0.110 |
Why?
|
| Pulmonary Artery | 1 | 2012 | 37 | 0.110 |
Why?
|
| Scrub Typhus | 5 | 1988 | 6 | 0.100 |
Why?
|
| Cytosol | 1 | 2012 | 85 | 0.100 |
Why?
|
| Cell Line, Tumor | 5 | 2013 | 2128 | 0.100 |
Why?
|
| Sesquiterpenes | 1 | 2011 | 30 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2020 | 605 | 0.100 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2012 | 195 | 0.100 |
Why?
|
| Triterpenes | 1 | 2011 | 12 | 0.100 |
Why?
|
| Angioplasty, Balloon | 1 | 2011 | 4 | 0.100 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2011 | 4 | 0.100 |
Why?
|
| Alkaloids | 1 | 2011 | 38 | 0.100 |
Why?
|
| Ventricular Remodeling | 2 | 2008 | 59 | 0.100 |
Why?
|
| Chromatography, Affinity | 1 | 2011 | 64 | 0.100 |
Why?
|
| Immunologic Factors | 1 | 2011 | 44 | 0.100 |
Why?
|
| Bilirubin | 1 | 2011 | 17 | 0.100 |
Why?
|
| Case-Control Studies | 4 | 2012 | 1056 | 0.100 |
Why?
|
| Stress, Psychological | 1 | 2016 | 541 | 0.100 |
Why?
|
| Serpins | 1 | 2011 | 26 | 0.100 |
Why?
|
| Nerve Growth Factors | 1 | 2011 | 33 | 0.100 |
Why?
|
| Coronary Disease | 1 | 2012 | 113 | 0.100 |
Why?
|
| Ethylamines | 1 | 2010 | 2 | 0.100 |
Why?
|
| Sulfur Compounds | 1 | 2010 | 7 | 0.100 |
Why?
|
| Eye Proteins | 1 | 2011 | 46 | 0.100 |
Why?
|
| Motor Activity | 1 | 2013 | 393 | 0.100 |
Why?
|
| Receptors, CCR2 | 2 | 2008 | 26 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 468 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 901 | 0.100 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2011 | 78 | 0.100 |
Why?
|
| Plasmodium yoelii | 3 | 2017 | 10 | 0.100 |
Why?
|
| Phytotherapy | 2 | 2010 | 62 | 0.090 |
Why?
|
| Sulfides | 1 | 2010 | 58 | 0.090 |
Why?
|
| Phosphorylation | 2 | 2017 | 878 | 0.090 |
Why?
|
| Polyethylene Glycols | 1 | 2010 | 80 | 0.090 |
Why?
|
| Eating | 2 | 2023 | 152 | 0.090 |
Why?
|
| Chymases | 1 | 2009 | 3 | 0.090 |
Why?
|
| Mastocytoma | 1 | 2009 | 4 | 0.090 |
Why?
|
| Homocysteine | 1 | 2009 | 18 | 0.090 |
Why?
|
| Chemokine CCL2 | 2 | 2008 | 82 | 0.090 |
Why?
|
| ras Proteins | 3 | 2006 | 49 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 3 | 2023 | 54 | 0.090 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2009 | 6 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 445 | 0.090 |
Why?
|
| Thrombocythemia, Essential | 1 | 2009 | 1 | 0.090 |
Why?
|
| Antigens, CD1 | 1 | 2009 | 4 | 0.090 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2009 | 21 | 0.090 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2009 | 8 | 0.090 |
Why?
|
| Reactive Oxygen Species | 2 | 2009 | 416 | 0.090 |
Why?
|
| Antibodies, Viral | 4 | 1986 | 252 | 0.090 |
Why?
|
| Reference Standards | 1 | 2009 | 52 | 0.090 |
Why?
|
| Drug Discovery | 1 | 2010 | 77 | 0.090 |
Why?
|
| Reference Values | 3 | 2004 | 204 | 0.090 |
Why?
|
| Heart Rupture, Post-Infarction | 1 | 2008 | 2 | 0.090 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2008 | 17 | 0.090 |
Why?
|
| Rickettsia Infections | 1 | 1988 | 2 | 0.080 |
Why?
|
| Predictive Value of Tests | 4 | 2012 | 424 | 0.080 |
Why?
|
| Orientia tsutsugamushi | 4 | 1980 | 7 | 0.080 |
Why?
|
| Exercise | 1 | 2013 | 524 | 0.080 |
Why?
|
| Sphingolipids | 1 | 2008 | 13 | 0.080 |
Why?
|
| Rats | 4 | 2011 | 3261 | 0.080 |
Why?
|
| Adaptation, Physiological | 2 | 2006 | 106 | 0.080 |
Why?
|
| Heart Ventricles | 1 | 2008 | 121 | 0.080 |
Why?
|
| Young Adult | 3 | 2019 | 4012 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 4 | 2019 | 1530 | 0.080 |
Why?
|
| Autoantigens | 1 | 2008 | 82 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 72 | 0.080 |
Why?
|
| Ligands | 1 | 2008 | 317 | 0.080 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2008 | 84 | 0.080 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2007 | 91 | 0.070 |
Why?
|
| Regression Analysis | 4 | 2014 | 429 | 0.070 |
Why?
|
| Phosphatidylcholines | 1 | 2006 | 45 | 0.070 |
Why?
|
| Binding Sites | 1 | 2008 | 597 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2006 | 94 | 0.070 |
Why?
|
| Gene Expression | 2 | 2008 | 639 | 0.070 |
Why?
|
| MAP Kinase Signaling System | 2 | 2005 | 162 | 0.070 |
Why?
|
| Umbilical Cord | 1 | 2006 | 13 | 0.070 |
Why?
|
| Coronary Artery Bypass | 1 | 2006 | 43 | 0.070 |
Why?
|
| Nalidixic Acid | 1 | 2006 | 2 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2008 | 231 | 0.070 |
Why?
|
| Propanolamines | 1 | 2006 | 12 | 0.070 |
Why?
|
| Alveolar Process | 1 | 2005 | 3 | 0.070 |
Why?
|
| Mandible | 1 | 2005 | 15 | 0.070 |
Why?
|
| Mastication | 1 | 2005 | 19 | 0.070 |
Why?
|
| RNA, Bacterial | 1 | 2006 | 29 | 0.070 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2006 | 50 | 0.070 |
Why?
|
| Antibodies, Bacterial | 3 | 1980 | 107 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2003 | 122 | 0.070 |
Why?
|
| Esters | 3 | 2011 | 28 | 0.070 |
Why?
|
| Receptors, CCR5 | 1 | 2005 | 59 | 0.070 |
Why?
|
| Carbazoles | 1 | 2006 | 43 | 0.070 |
Why?
|
| Biotin | 1 | 2005 | 21 | 0.070 |
Why?
|
| Cross-Linking Reagents | 1 | 2005 | 48 | 0.070 |
Why?
|
| Quinolines | 1 | 2005 | 60 | 0.070 |
Why?
|
| Herpesviridae | 5 | 1971 | 13 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2017 | 150 | 0.070 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2020 | 342 | 0.070 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2006 | 78 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2009 | 1152 | 0.070 |
Why?
|
| Constriction, Pathologic | 1 | 2005 | 8 | 0.070 |
Why?
|
| Chi-Square Distribution | 3 | 2012 | 213 | 0.070 |
Why?
|
| Sulfhydryl Compounds | 1 | 2005 | 46 | 0.070 |
Why?
|
| Mice, Nude | 4 | 1980 | 323 | 0.060 |
Why?
|
| ROC Curve | 2 | 2018 | 138 | 0.060 |
Why?
|
| Lymphatic Metastasis | 3 | 2000 | 63 | 0.060 |
Why?
|
| Cross-Sectional Studies | 4 | 2019 | 2561 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 298 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 592 | 0.060 |
Why?
|
| Escherichia coli Proteins | 1 | 2006 | 119 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 1 | 2005 | 122 | 0.060 |
Why?
|
| L-Selectin | 1 | 2004 | 2 | 0.060 |
Why?
|
| Creatinine | 2 | 2018 | 101 | 0.060 |
Why?
|
| Acute-Phase Proteins | 1 | 2004 | 14 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2009 | 874 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2019 | 480 | 0.060 |
Why?
|
| Receptors, CXCR3 | 1 | 2003 | 30 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2003 | 10 | 0.060 |
Why?
|
| Phosphatidylethanolamines | 1 | 2023 | 22 | 0.060 |
Why?
|
| Famotidine | 1 | 2003 | 1 | 0.060 |
Why?
|
| Histamine H2 Antagonists | 1 | 2003 | 3 | 0.060 |
Why?
|
| Synaptotagmin I | 1 | 2023 | 3 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 1 | 2004 | 70 | 0.060 |
Why?
|
| Drug Tolerance | 1 | 2003 | 38 | 0.060 |
Why?
|
| Chemokine CXCL10 | 1 | 2003 | 37 | 0.060 |
Why?
|
| Philippines | 2 | 2013 | 72 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2005 | 203 | 0.060 |
Why?
|
| Combined Modality Therapy | 3 | 2009 | 142 | 0.060 |
Why?
|
| Chronotherapy | 1 | 2003 | 1 | 0.060 |
Why?
|
| Anti-Ulcer Agents | 1 | 2003 | 5 | 0.060 |
Why?
|
| Antigens, Protozoan | 2 | 2017 | 71 | 0.060 |
Why?
|
| Down-Regulation | 3 | 2012 | 420 | 0.060 |
Why?
|
| Gastric Acid | 1 | 2003 | 8 | 0.060 |
Why?
|
| Incidence | 2 | 2017 | 882 | 0.060 |
Why?
|
| Burkitt Lymphoma | 4 | 1971 | 23 | 0.060 |
Why?
|
| Benzimidazoles | 1 | 2003 | 36 | 0.060 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2003 | 44 | 0.060 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2016 | 60 | 0.060 |
Why?
|
| Mammals | 1 | 2023 | 96 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2020 | 897 | 0.060 |
Why?
|
| Logistic Models | 3 | 2011 | 894 | 0.050 |
Why?
|
| Neovascularization, Physiologic | 1 | 2003 | 70 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 355 | 0.050 |
Why?
|
| Antibody Formation | 2 | 1980 | 73 | 0.050 |
Why?
|
| Unemployment | 1 | 2021 | 23 | 0.050 |
Why?
|
| Erythrocytes | 2 | 1979 | 107 | 0.050 |
Why?
|
| Thymus Gland | 2 | 1980 | 77 | 0.050 |
Why?
|
| Nigeria | 2 | 2011 | 74 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 4 | 2015 | 649 | 0.050 |
Why?
|
| Triglycerides | 2 | 2014 | 129 | 0.050 |
Why?
|
| Drug Therapy, Combination | 3 | 2009 | 217 | 0.050 |
Why?
|
| Kinetics | 2 | 2020 | 650 | 0.050 |
Why?
|
| Coronary Thrombosis | 2 | 2012 | 6 | 0.050 |
Why?
|
| Cell Proliferation | 3 | 2011 | 1149 | 0.050 |
Why?
|
| Antigens | 2 | 2017 | 56 | 0.050 |
Why?
|
| Mutation | 1 | 2006 | 1023 | 0.050 |
Why?
|
| Plant Leaves | 2 | 2011 | 110 | 0.050 |
Why?
|
| Cell Division | 3 | 2006 | 296 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2023 | 200 | 0.050 |
Why?
|
| Prosthesis Design | 1 | 2020 | 26 | 0.050 |
Why?
|
| Muromonab-CD3 | 1 | 2000 | 1 | 0.050 |
Why?
|
| Neck Dissection | 1 | 2000 | 1 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2017 | 528 | 0.050 |
Why?
|
| Paclitaxel | 2 | 2012 | 48 | 0.050 |
Why?
|
| Postoperative Care | 1 | 2000 | 18 | 0.050 |
Why?
|
| Pleural Effusion | 1 | 2020 | 8 | 0.050 |
Why?
|
| Up-Regulation | 3 | 2009 | 490 | 0.050 |
Why?
|
| Immune Tolerance | 1 | 1980 | 61 | 0.050 |
Why?
|
| Homozygote | 1 | 1980 | 75 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2000 | 114 | 0.050 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 1980 | 19 | 0.050 |
Why?
|
| Uranium | 1 | 2020 | 19 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 3 | 2006 | 97 | 0.050 |
Why?
|
| Adsorption | 1 | 2020 | 67 | 0.050 |
Why?
|
| Age Factors | 6 | 2014 | 1007 | 0.050 |
Why?
|
| Embryo, Mammalian | 1 | 2020 | 152 | 0.050 |
Why?
|
| Seawater | 1 | 2020 | 46 | 0.050 |
Why?
|
| Mites | 3 | 1988 | 8 | 0.040 |
Why?
|
| Apolipoprotein A-I | 1 | 2019 | 21 | 0.040 |
Why?
|
| Immunoglobulin G | 4 | 2003 | 232 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2010 | 984 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 211 | 0.040 |
Why?
|
| Cross Reactions | 1 | 1979 | 83 | 0.040 |
Why?
|
| Vietnam | 1 | 2019 | 38 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2010 | 107 | 0.040 |
Why?
|
| Workplace | 1 | 2020 | 72 | 0.040 |
Why?
|
| Flavonoids | 3 | 2005 | 78 | 0.040 |
Why?
|
| Antibodies, Heterophile | 1 | 1978 | 2 | 0.040 |
Why?
|
| Haptens | 1 | 1978 | 19 | 0.040 |
Why?
|
| T-Lymphocytes | 5 | 2011 | 341 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 2 | 2009 | 137 | 0.040 |
Why?
|
| Rehabilitation | 1 | 2018 | 4 | 0.040 |
Why?
|
| Homes for the Aged | 1 | 2018 | 14 | 0.040 |
Why?
|
| Heart Rate | 2 | 2011 | 248 | 0.040 |
Why?
|
| Neoplasm Transplantation | 2 | 1978 | 114 | 0.040 |
Why?
|
| K562 Cells | 1 | 2017 | 31 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2017 | 8 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2017 | 26 | 0.040 |
Why?
|
| Social Welfare | 1 | 2018 | 30 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2018 | 91 | 0.040 |
Why?
|
| Public Sector | 1 | 2017 | 20 | 0.040 |
Why?
|
| Cell Membrane Permeability | 1 | 2017 | 49 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2018 | 43 | 0.040 |
Why?
|
| Lymphoid Tissue | 1 | 1977 | 17 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2017 | 20 | 0.040 |
Why?
|
| Fluorescence | 1 | 2017 | 117 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 2017 | 72 | 0.040 |
Why?
|
| Cause of Death | 1 | 2017 | 154 | 0.040 |
Why?
|
| Survival Rate | 1 | 2017 | 310 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2017 | 86 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2017 | 235 | 0.040 |
Why?
|
| Sporozoites | 1 | 2015 | 6 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2020 | 1422 | 0.030 |
Why?
|
| Health Behavior | 1 | 2020 | 491 | 0.030 |
Why?
|
| Lysine | 2 | 2011 | 104 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2009 | 286 | 0.030 |
Why?
|
| Cholesterol | 2 | 2006 | 194 | 0.030 |
Why?
|
| Hypertension | 2 | 2018 | 770 | 0.030 |
Why?
|
| Lipoproteins, LDL | 1 | 2014 | 61 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2005 | 93 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 841 | 0.030 |
Why?
|
| Scattering, Radiation | 1 | 2013 | 45 | 0.030 |
Why?
|
| Pyridines | 2 | 2005 | 113 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2015 | 608 | 0.030 |
Why?
|
| Pertussis Toxin | 2 | 2003 | 27 | 0.030 |
Why?
|
| Government Regulation | 1 | 2013 | 15 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 14 | 0.030 |
Why?
|
| Cross-Over Studies | 2 | 2003 | 102 | 0.030 |
Why?
|
| Risk | 2 | 2011 | 256 | 0.030 |
Why?
|
| Guinea Pigs | 3 | 1979 | 141 | 0.030 |
Why?
|
| Uric Acid | 1 | 2012 | 26 | 0.030 |
Why?
|
| Hela Cells | 1 | 2013 | 344 | 0.030 |
Why?
|
| Environmental Monitoring | 1 | 2013 | 188 | 0.030 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2012 | 13 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2003 | 423 | 0.030 |
Why?
|
| Cola | 1 | 2011 | 1 | 0.030 |
Why?
|
| Hexanes | 1 | 2011 | 2 | 0.030 |
Why?
|
| Chloroform | 1 | 2011 | 3 | 0.030 |
Why?
|
| Hemolytic Plaque Technique | 3 | 1982 | 6 | 0.030 |
Why?
|
| Fibrosis | 1 | 2012 | 146 | 0.030 |
Why?
|
| Receptors, Interleukin-8 | 1 | 2011 | 1 | 0.030 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2011 | 4 | 0.030 |
Why?
|
| Dental Occlusion | 1 | 2011 | 2 | 0.030 |
Why?
|
| Cytokines | 1 | 2015 | 569 | 0.030 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2011 | 94 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2013 | 210 | 0.030 |
Why?
|
| Solvents | 1 | 2011 | 93 | 0.030 |
Why?
|
| Angiography | 1 | 2011 | 15 | 0.030 |
Why?
|
| Haplorhini | 1 | 1971 | 21 | 0.030 |
Why?
|
| Biological Factors | 1 | 2010 | 6 | 0.020 |
Why?
|
| Arginine | 1 | 2011 | 62 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2011 | 89 | 0.020 |
Why?
|
| Cell Survival | 1 | 2013 | 818 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 164 | 0.020 |
Why?
|
| Myocardial Ischemia | 1 | 2010 | 72 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 517 | 0.020 |
Why?
|
| Ticlopidine | 1 | 2009 | 15 | 0.020 |
Why?
|
| Palatine Tonsil | 2 | 1979 | 4 | 0.020 |
Why?
|
| Transplantation, Homologous | 2 | 1979 | 35 | 0.020 |
Why?
|
| Tunica Intima | 1 | 2009 | 21 | 0.020 |
Why?
|
| Valine | 1 | 2009 | 31 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2009 | 38 | 0.020 |
Why?
|
| Cesarean Section | 1 | 2009 | 53 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 1425 | 0.020 |
Why?
|
| Angiotensin II | 1 | 2009 | 92 | 0.020 |
Why?
|
| Hydroxyurea | 1 | 2009 | 34 | 0.020 |
Why?
|
| Antigen Presentation | 1 | 2009 | 54 | 0.020 |
Why?
|
| Bed Rest | 1 | 2008 | 2 | 0.020 |
Why?
|
| Pericardiocentesis | 1 | 2008 | 2 | 0.020 |
Why?
|
| Body Fat Distribution | 1 | 2008 | 23 | 0.020 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2008 | 8 | 0.020 |
Why?
|
| Typhus, Endemic Flea-Borne | 1 | 1988 | 2 | 0.020 |
Why?
|
| Disease Vectors | 1 | 1988 | 10 | 0.020 |
Why?
|
| Graft Rejection | 2 | 1979 | 38 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2009 | 84 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 727 | 0.020 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2008 | 3 | 0.020 |
Why?
|
| Rats, Inbred WKY | 1 | 2008 | 23 | 0.020 |
Why?
|
| Scavenger Receptors, Class B | 1 | 2008 | 7 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2009 | 97 | 0.020 |
Why?
|
| Lymphoma | 4 | 1979 | 37 | 0.020 |
Why?
|
| Safety | 1 | 2008 | 48 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2008 | 154 | 0.020 |
Why?
|
| Echocardiography | 1 | 2008 | 144 | 0.020 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2006 | 38 | 0.020 |
Why?
|
| Taiwan | 3 | 1971 | 11 | 0.020 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2006 | 34 | 0.020 |
Why?
|
| Heart | 1 | 2008 | 178 | 0.020 |
Why?
|
| Hemoglobin A | 1 | 2006 | 4 | 0.020 |
Why?
|
| Cricetulus | 1 | 2006 | 74 | 0.020 |
Why?
|
| CHO Cells | 1 | 2006 | 107 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2006 | 63 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2009 | 871 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 608 | 0.020 |
Why?
|
| Cricetinae | 1 | 2006 | 217 | 0.020 |
Why?
|
| Inflammation | 1 | 2011 | 577 | 0.020 |
Why?
|
| Dental Stress Analysis | 1 | 2005 | 4 | 0.020 |
Why?
|
| Molar | 1 | 2005 | 6 | 0.020 |
Why?
|
| Pravastatin | 1 | 2005 | 6 | 0.020 |
Why?
|
| U937 Cells | 1 | 2005 | 27 | 0.020 |
Why?
|
| Capsid Proteins | 1 | 1986 | 60 | 0.020 |
Why?
|
| Antigens, Viral | 3 | 1986 | 42 | 0.020 |
Why?
|
| Chemokines | 1 | 2006 | 89 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2005 | 38 | 0.020 |
Why?
|
| Antigens, Viral, Tumor | 1 | 1985 | 8 | 0.020 |
Why?
|
| S Phase | 1 | 2005 | 36 | 0.020 |
Why?
|
| Bone Density | 1 | 2005 | 76 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2005 | 21 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2005 | 202 | 0.020 |
Why?
|
| Immunoglobulin A | 1 | 1985 | 58 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2005 | 110 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2009 | 1353 | 0.020 |
Why?
|
| Capsid | 1 | 1985 | 51 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2006 | 245 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 73 | 0.020 |
Why?
|
| Recurrence | 1 | 2005 | 125 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2005 | 90 | 0.020 |
Why?
|
| Acute Disease | 1 | 2005 | 141 | 0.020 |
Why?
|
| Amides | 1 | 2005 | 66 | 0.020 |
Why?
|
| Pregnancy | 1 | 2009 | 1503 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2005 | 157 | 0.020 |
Why?
|
| Disease Progression | 1 | 2006 | 580 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2005 | 184 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2003 | 18 | 0.010 |
Why?
|
| Gastric Acidity Determination | 1 | 2003 | 2 | 0.010 |
Why?
|
| Gastrins | 1 | 2003 | 9 | 0.010 |
Why?
|
| Bradykinin | 1 | 2003 | 22 | 0.010 |
Why?
|
| Seroepidemiologic Studies | 1 | 2003 | 67 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2006 | 328 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2003 | 89 | 0.010 |
Why?
|
| Blood Pressure Determination | 1 | 2003 | 53 | 0.010 |
Why?
|
| Laminin | 1 | 2003 | 59 | 0.010 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2003 | 3 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2003 | 46 | 0.010 |
Why?
|
| Omeprazole | 1 | 2003 | 6 | 0.010 |
Why?
|
| Monitoring, Ambulatory | 1 | 2003 | 13 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2003 | 170 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2003 | 115 | 0.010 |
Why?
|
| Methods | 3 | 1971 | 12 | 0.010 |
Why?
|
| Collagen | 1 | 2003 | 162 | 0.010 |
Why?
|
| Forssman Antigen | 1 | 1982 | 1 | 0.010 |
Why?
|
| Antigens, Heterophile | 1 | 1982 | 1 | 0.010 |
Why?
|
| Transfection | 1 | 2003 | 496 | 0.010 |
Why?
|
| Antibodies, Neoplasm | 1 | 1982 | 16 | 0.010 |
Why?
|
| Bone Marrow | 2 | 1978 | 34 | 0.010 |
Why?
|
| Trombiculidae | 1 | 1980 | 1 | 0.010 |
Why?
|
| Antibody-Producing Cells | 1 | 1980 | 5 | 0.010 |
Why?
|
| Arachnid Vectors | 1 | 1980 | 3 | 0.010 |
Why?
|
| Child, Preschool | 3 | 1980 | 1318 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1980 | 117 | 0.010 |
Why?
|
| Rodentia | 1 | 1980 | 41 | 0.010 |
Why?
|
| Immunoglobulin Light Chains | 1 | 1980 | 5 | 0.010 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1980 | 14 | 0.010 |
Why?
|
| Trypsin | 1 | 1980 | 39 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 1980 | 75 | 0.010 |
Why?
|
| Heterozygote | 1 | 1980 | 91 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2008 | 794 | 0.010 |
Why?
|
| Serologic Tests | 1 | 1980 | 43 | 0.010 |
Why?
|
| Absorption | 1 | 1979 | 22 | 0.010 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1979 | 20 | 0.010 |
Why?
|
| Species Specificity | 1 | 1980 | 233 | 0.010 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 1980 | 62 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1979 | 75 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1979 | 22 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1978 | 3 | 0.010 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1979 | 10 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1978 | 23 | 0.010 |
Why?
|
| Horses | 1 | 1978 | 24 | 0.010 |
Why?
|
| Dinitrobenzenes | 1 | 1978 | 17 | 0.010 |
Why?
|
| Flagellin | 1 | 1978 | 16 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 1978 | 21 | 0.010 |
Why?
|
| Disease Outbreaks | 1 | 1980 | 155 | 0.010 |
Why?
|
| Fetal Blood | 1 | 1979 | 47 | 0.010 |
Why?
|
| Epitopes | 1 | 1978 | 145 | 0.010 |
Why?
|
| Cattle | 1 | 1979 | 472 | 0.010 |
Why?
|
| Clone Cells | 1 | 1977 | 46 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 1977 | 87 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1979 | 351 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 2 | 1973 | 73 | 0.010 |
Why?
|
| Immune Sera | 2 | 1971 | 59 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 1973 | 240 | 0.010 |
Why?
|
| Infectious Mononucleosis | 1 | 1971 | 1 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 1971 | 36 | 0.010 |
Why?
|
| Macaca | 1 | 1971 | 38 | 0.010 |
Why?
|
| Blood Specimen Collection | 1 | 1970 | 12 | 0.010 |
Why?
|
| Rabbits | 1 | 1971 | 278 | 0.010 |
Why?
|
| gamma-Globulins | 1 | 1970 | 5 | 0.010 |
Why?
|
| Measles | 1 | 1970 | 6 | 0.010 |
Why?
|
| Rubella | 1 | 1970 | 13 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1971 | 360 | 0.010 |
Why?
|
| Encephalitis, Japanese | 1 | 1966 | 3 | 0.000 |
Why?
|
| ABO Blood-Group System | 1 | 1982 | 5 | 0.000 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1982 | 18 | 0.000 |
Why?
|
| Liposomes | 1 | 1982 | 107 | 0.000 |
Why?
|
| Smoking | 1 | 1986 | 903 | 0.000 |
Why?
|
| Rosette Formation | 1 | 1978 | 1 | 0.000 |
Why?
|
| Complement Fixation Tests | 1 | 1978 | 2 | 0.000 |
Why?
|
| Neoplasms, Experimental | 1 | 1978 | 36 | 0.000 |
Why?
|
| Granulocytes | 1 | 1978 | 28 | 0.000 |
Why?
|
| Granuloma | 1 | 1978 | 23 | 0.000 |
Why?
|
| Prognosis | 1 | 1978 | 707 | 0.000 |
Why?
|
| Filtration | 1 | 1970 | 14 | 0.000 |
Why?
|
| Paper | 1 | 1970 | 22 | 0.000 |
Why?
|
| Tongue Neoplasms | 1 | 1969 | 10 | 0.000 |
Why?
|
| Leukemia | 1 | 1969 | 54 | 0.000 |
Why?
|
| China | 1 | 1969 | 178 | 0.000 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1969 | 248 | 0.000 |
Why?
|
| Infant | 1 | 1969 | 1014 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 1969 | 336 | 0.000 |
Why?
|